Granules India clears Q2 results, 3 acquisitions including Germany entry and renewable stakes

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹542.95

prior close

₹555.40

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%+2.4% vs market

Pharmaceuticals peers, median of 157sector-0.1%+2.2% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Smallcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

+0.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-0.4+2.4-0.1+2.2

Next day

+1.4-0.2+1.6-0.5+1.8

+3.5+0.5+3.0-0.4+3.9

+3.2-0.6+3.8-1.1+4.3

+1.8-1.0+2.8-1.4+3.2

+1.1-1.1+2.2-1.6+2.7

-2.0-2.9+0.9-3.3+1.3

15d

+4.0-3.1+7.1-3.4+7.4

+5.3-3.9+9.2-4.3+9.6

+8.5-5.3+13.9-6.9+15.4

+3.1-6.6+9.7-8.8+11.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 and H1 FY26 unaudited results. Cleared 100% acquisition of Germany's Optus 1039 GmbH for about EUR 28,400 to set up a pharma subsidiary and enter the European B2C market. Also approved 26% stakes in two Ecoren Energy India SPVs, Renpow Narayankhed (INR 13.74 Cr) and Renpow Kalyandurg (INR 3.50 Cr), for captive solar and wind power at Telangana and Andhra Pradesh facilities. Renewable energy deals are related party transactions at arm's length.

Likely market impact

Strategic expansion into European pharma and lower energy costs via captive renewables; deal sizes are small so limited near-term financial impact.